S&P 500   4,526.01 (-1.12%)
DOW   34,487.88 (-0.44%)
QQQ   382.95 (-1.79%)
AAPL   162.44 (-0.81%)
MSFT   323.10 (-1.94%)
FB   305.04 (-1.72%)
GOOGL   2,824.20 (-1.23%)
AMZN   3,395.56 (-1.22%)
TSLA   1,023.75 (-5.61%)
NVDA   306.15 (-4.70%)
BABA   112.16 (-8.07%)
NIO   32.75 (-9.53%)
CGC   10.11 (-2.41%)
AMD   143.05 (-5.06%)
GE   93.06 (-2.28%)
MU   82.50 (-0.46%)
T   23.37 (+1.39%)
F   19.41 (-2.32%)
DIS   146.05 (-0.78%)
PFE   53.75 (+1.34%)
AMC   28.22 (-6.80%)
ACB   5.93 (-3.42%)
BA   197.13 (-2.59%)
S&P 500   4,526.01 (-1.12%)
DOW   34,487.88 (-0.44%)
QQQ   382.95 (-1.79%)
AAPL   162.44 (-0.81%)
MSFT   323.10 (-1.94%)
FB   305.04 (-1.72%)
GOOGL   2,824.20 (-1.23%)
AMZN   3,395.56 (-1.22%)
TSLA   1,023.75 (-5.61%)
NVDA   306.15 (-4.70%)
BABA   112.16 (-8.07%)
NIO   32.75 (-9.53%)
CGC   10.11 (-2.41%)
AMD   143.05 (-5.06%)
GE   93.06 (-2.28%)
MU   82.50 (-0.46%)
T   23.37 (+1.39%)
F   19.41 (-2.32%)
DIS   146.05 (-0.78%)
PFE   53.75 (+1.34%)
AMC   28.22 (-6.80%)
ACB   5.93 (-3.42%)
BA   197.13 (-2.59%)
S&P 500   4,526.01 (-1.12%)
DOW   34,487.88 (-0.44%)
QQQ   382.95 (-1.79%)
AAPL   162.44 (-0.81%)
MSFT   323.10 (-1.94%)
FB   305.04 (-1.72%)
GOOGL   2,824.20 (-1.23%)
AMZN   3,395.56 (-1.22%)
TSLA   1,023.75 (-5.61%)
NVDA   306.15 (-4.70%)
BABA   112.16 (-8.07%)
NIO   32.75 (-9.53%)
CGC   10.11 (-2.41%)
AMD   143.05 (-5.06%)
GE   93.06 (-2.28%)
MU   82.50 (-0.46%)
T   23.37 (+1.39%)
F   19.41 (-2.32%)
DIS   146.05 (-0.78%)
PFE   53.75 (+1.34%)
AMC   28.22 (-6.80%)
ACB   5.93 (-3.42%)
BA   197.13 (-2.59%)
S&P 500   4,526.01 (-1.12%)
DOW   34,487.88 (-0.44%)
QQQ   382.95 (-1.79%)
AAPL   162.44 (-0.81%)
MSFT   323.10 (-1.94%)
FB   305.04 (-1.72%)
GOOGL   2,824.20 (-1.23%)
AMZN   3,395.56 (-1.22%)
TSLA   1,023.75 (-5.61%)
NVDA   306.15 (-4.70%)
BABA   112.16 (-8.07%)
NIO   32.75 (-9.53%)
CGC   10.11 (-2.41%)
AMD   143.05 (-5.06%)
GE   93.06 (-2.28%)
MU   82.50 (-0.46%)
T   23.37 (+1.39%)
F   19.41 (-2.32%)
DIS   146.05 (-0.78%)
PFE   53.75 (+1.34%)
AMC   28.22 (-6.80%)
ACB   5.93 (-3.42%)
BA   197.13 (-2.59%)
NASDAQ:AMYT

Amryt Pharma Stock Forecast, Price & News

$9.62
-0.11 (-1.13%)
(As of 12/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.44
$9.92
50-Day Range
$9.55
$12.24
52-Week Range
$9.23
$15.44
Volume
97,265 shs
Average Volume
83,928 shs
Market Capitalization
$611.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.75
30 days | 90 days | 365 days | Advanced Chart
Receive AMYT News and Ratings via Email

Sign-up to receive the latest news and ratings for Amryt Pharma and its competitors with MarketBeat's FREE daily newsletter.


Amryt Pharma logo

About Amryt Pharma

Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate, which is in Phase 3 EASE trial for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 that is in preclinical stage for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Headlines

Amryt Pharma (NASDAQ:AMYT) Sets New 52-Week Low at $9.23
November 30, 2021 |  americanbankingnews.com
Amryt Pharma (NASDAQ:AMYT) Sees Large Volume Increase
November 29, 2021 |  americanbankingnews.com
HC Wainwright Reaffirms "Buy" Rating for Amryt Pharma (NASDAQ:AMYT)
November 24, 2021 |  americanbankingnews.com
Amryt Pharma (NASDAQ:AMYT) Sees Strong Trading Volume
November 23, 2021 |  americanbankingnews.com
SVB Leerink Trims Amryt Pharma (NASDAQ:AMYT) Target Price to $19.00
November 23, 2021 |  americanbankingnews.com
Amryt Pharma drug application review with FDA extended three months
November 23, 2021 |  proactiveinvestors.com
Amryt Pharma (NASDAQ:AMYT) Shares Gap Down to $11.59
November 22, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AMYT
Fax
N/A
Employees
2,020
Year Founded
N/A

Sales & Book Value

Annual Sales
$182.61 million
Book Value
$1.93 per share

Profitability

Net Income
$-104.53 million
Pretax Margin
-47.77%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$611.83 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/03/2021
Today
12/03/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/03/2022

MarketRank

Overall MarketRank

1.83 out of 5 stars

Medical Sector

815th out of 1,391 stocks

Pharmaceutical Preparations Industry

384th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Amryt Pharma (NASDAQ:AMYT) Frequently Asked Questions

Is Amryt Pharma a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amryt Pharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Amryt Pharma stock.
View analyst ratings for Amryt Pharma
or view top-rated stocks.

Are investors shorting Amryt Pharma?

Amryt Pharma saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 161,500 shares, a decrease of 30.2% from the October 31st total of 231,300 shares. Based on an average daily volume of 121,000 shares, the days-to-cover ratio is currently 1.3 days.
View Amryt Pharma's Short Interest
.

When is Amryt Pharma's next earnings date?

Amryt Pharma is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Amryt Pharma
.

How were Amryt Pharma's earnings last quarter?

Amryt Pharma plc (NASDAQ:AMYT) issued its quarterly earnings data on Wednesday, November, 3rd. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.14. The business earned $56.52 million during the quarter, compared to analyst estimates of $52.34 million. Amryt Pharma had a negative net margin of 41.64% and a negative trailing twelve-month return on equity of 73.58%.
View Amryt Pharma's earnings history
.

What guidance has Amryt Pharma issued on next quarter's earnings?

Amryt Pharma issued an update on its FY 2021 earnings guidance on Monday, October, 11th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $220 million-$225 million, compared to the consensus revenue estimate of $221.14 million.

What price target have analysts set for AMYT?

4 equities research analysts have issued twelve-month price targets for Amryt Pharma's stock. Their forecasts range from $19.00 to $45.00. On average, they anticipate Amryt Pharma's stock price to reach $29.50 in the next twelve months. This suggests a possible upside of 206.7% from the stock's current price.
View analysts' price targets for Amryt Pharma
or view top-rated stocks among Wall Street analysts.

Who are Amryt Pharma's key executives?

Amryt Pharma's management team includes the following people:
  • Dr. Joseph A. Wiley, CEO & Director (Age 50, Pay $1.72M)
  • Mr. Rory P. Nealon, CFO, COO & Company Sec. (Age 53, Pay $931k)
  • Ms. Elizabeth Varki Jobes J.D., Sr. VP & Global Chief Compliance Officer (Age 54)
  • Mr. John McEvoy, Gen. Counsel
  • Mr. Stephen Joyce, VP of Global Marketing
  • Ms. Julie Eastwood, Head of HR
  • Ms. Derval O'Carroll, Head of Regulatory Affairs
  • Mr. Gerry Gilligan, Head of Manufacturing Supply Chain
  • Dr. Mark Sumeray, Chief Medical Officer (Age 55)
  • Mr. David Allmond, Chief Commercial Officer

What other stocks do shareholders of Amryt Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amryt Pharma investors own include Immunic (IMUX), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), Livongo Health (LVGO), Otonomy (OTIC), Akero Therapeutics (AKRO), Albireo Pharma (ALBO), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN).

What is Amryt Pharma's stock symbol?

Amryt Pharma trades on the NASDAQ under the ticker symbol "AMYT."

Who are Amryt Pharma's major shareholders?

Amryt Pharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Stonepine Capital Management LLC (9.15%), Rubric Capital Management LP (5.14%), MPM Asset Management LLC (4.21%), Highbridge Capital Management LLC (2.58%), Rock Springs Capital Management LP (2.04%) and Man Group plc (1.47%).

Which institutional investors are selling Amryt Pharma stock?

AMYT stock was sold by a variety of institutional investors in the last quarter, including Context Advisory LLC.

Which institutional investors are buying Amryt Pharma stock?

AMYT stock was bought by a variety of institutional investors in the last quarter, including Rubric Capital Management LP, Stonepine Capital Management LLC, MPM Asset Management LLC, Rock Springs Capital Management LP, Highbridge Capital Management LLC, Man Group plc, Clearline Capital LP, and New Leaf Venture Partners L.L.C..

How do I buy shares of Amryt Pharma?

Shares of AMYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amryt Pharma's stock price today?

One share of AMYT stock can currently be purchased for approximately $9.62.

How much money does Amryt Pharma make?

Amryt Pharma has a market capitalization of $611.83 million and generates $182.61 million in revenue each year. The company earns $-104.53 million in net income (profit) each year or ($0.48) on an earnings per share basis.

How many employees does Amryt Pharma have?

Amryt Pharma employs 2,020 workers across the globe.

What is Amryt Pharma's official website?

The official website for Amryt Pharma is www.amrytpharma.com.

Where are Amryt Pharma's headquarters?

How can I contact Amryt Pharma?

Amryt Pharma's mailing address is DEPT 920A 196 HIGH ROAD WOOD GREEN, LONDON X0, D02 CR98. The company can be reached via phone at 353-1518-0200 or via email at [email protected].


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.